TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HCW Biologics ( (HCWB) ) has issued an announcement.
HCW Biologics Inc. and WY Biotech Co., Ltd. have agreed to extend the payment date for a $7.0 million upfront license fee under their worldwide exclusive license agreement to September 30, 2025. However, WY Biotech has not finalized necessary agreements with its partners and may not meet the new deadline, prompting ongoing negotiations for further revisions to the agreement.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
HCW Biologics is currently struggling with significant financial challenges, including declining revenues and high leverage. While technical indicators show some neutral momentum, the valuation remains unattractive due to ongoing losses. Recent corporate actions suggest potential for improvement, but risks remain high.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
HCW Biologics Inc. operates in the biotechnology industry, focusing on developing innovative biologic therapies.
Average Trading Volume: 1,584,801
Technical Sentiment Signal: Sell
Current Market Cap: $9.96M
See more insights into HCWB stock on TipRanks’ Stock Analysis page.